XENE241220C40000
- 2.65
- 0.000.00%
Xenon Pharmaceuticals Newsroom
H.C. Wainwright Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $53
Xenon Pharmaceuticals Analyst Ratings
Promising Efficacy and Tolerability: Douglas Tsao's Buy Rating on Xenon Pharmaceuticals' Azetukalner
TD Cowen Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Raises Target Price to $56
TD Cowen Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
A Quick Look at Today's Ratings for Xenon Pharmaceuticals(XENE.US), With a Forecast Between $53 to $60
Xenon Pharmaceuticals Price Target Maintained With a $60.00/Share by Needham
Xenon Pharmaceuticals: Strategic Advancements and Promising Clinical Developments Earn a Buy Rating
J.P. Morgan Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating
Raymond James Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Cuts Target Price to $50
Stifel Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $62
H.C. Wainwright Initiates Xenon Pharmaceuticals(XENE.US) With Buy Rating, Announces Target Price $53
RBC Capital Maintains Xenon Pharmaceuticals(XENE.US) With Buy Rating, Maintains Target Price $55
Press Release: Xenon Expands Leadership Team With Matthew D. Ronsheim, Ph.D. as Chief Operating Officer
Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $60
Buy Rating Affirmed: Xenon Pharmaceuticals' Promising Clinical Trials and Pipeline Advancement
Xenon Pharmaceuticals Analyst Ratings
RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target